These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 30977935)

  • 1. Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan.
    Edahiro Y; Araki M; Inano T; Ito M; Morishita S; Misawa K; Fukuda Y; Imai M; Ohsaka A; Komatsu N
    Eur J Haematol; 2019 Jun; 102(6):516-520. PubMed ID: 30977935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical features and next-generation sequencing landscape of essential thrombocythemia, prefibrotic primary myelofibrosis, and overt fibrotic primary myelofibrosis: a Chinese monocentric retrospective study.
    Zhang L; Ye X; Luo S; Xu X; Wang S; Jin K; Zheng Y; Zhu X; Chen D; Jin J; Huang J
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2383-2392. PubMed ID: 35731275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia.
    Kamiunten A; Shide K; Kameda T; Ito M; Sekine M; Kubuki Y; Hidaka T; Akizuki K; Tahira Y; Toyama T; Kawano N; Marutsuka K; Maeda K; Takeuchi M; Kawano H; Sato S; Ishizaki J; Shimoda H; Yamashita K; Matsuoka H; Shimoda K
    Int J Hematol; 2018 Oct; 108(4):411-415. PubMed ID: 29987745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.
    Yönal İ; Dağlar-Aday A; Akadam-Teker B; Yılmaz C; Nalçacı M; Yavuz AS; Sargın FD
    Turk J Haematol; 2016 Jun; 33(2):94-101. PubMed ID: 25913509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
    Barbui T; Thiele J; Vannucchi AM; Tefferi A
    Blood Cancer J; 2015 Aug; 5(8):e337. PubMed ID: 26832847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Clinical and Molecular Features Between Patients With Essential Thrombocythemia and Early/Prefibrotic Primary Myelofibrosis Presenting With Thrombocytosis in Taiwan.
    Kuo MC; Chuang WY; Chang H; Lin TH; Wu JH; Lin TL; Ou CW; Hung YS; Huang TY; Huang YJ; Wang PN; Shih LY
    Am J Clin Pathol; 2023 May; 159(5):474-483. PubMed ID: 36857745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The morphology features of bone marrow in the prefibrotic-early primary myelofibrosis].
    Gong XB; Zhang XH; Lu XG; Tang QS; Gao X; Yang J
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jan; 33(1):25-30. PubMed ID: 22575188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.
    Barbui T; Thiele J; Passamonti F; Rumi E; Boveri E; Ruggeri M; Rodeghiero F; d'Amore ES; Randi ML; Bertozzi I; Marino F; Vannucchi AM; Antonioli E; Carrai V; Gisslinger H; Buxhofer-Ausch V; Müllauer L; Carobbio A; Gianatti A; Gangat N; Hanson CA; Tefferi A
    J Clin Oncol; 2011 Aug; 29(23):3179-84. PubMed ID: 21747083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter.
    Barosi G
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):129-40. PubMed ID: 25189724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Essential thrombocythaemia with mutation in
    Alvarez-Larran A; Martínez D; Arenillas L; Rubio A; Arellano-Rodrigo E; Hernández Boluda JC; Papaleo N; Caballero G; Martínez C; Ferrer-Marín F; Mata MI; Pérez-Encinas M; Durán MA; Alonso JM; Carreño-Tarragona G; Alonso JM; Noya S; Magro E; Pérez R; López-Guerra M; Pastor-Galán I; Cervantes F; Besses C; Colomo L; Rozman M
    J Clin Pathol; 2018 Nov; 71(11):975-980. PubMed ID: 29934356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Utility of the bone marrow biopsy in the diagnosis of essential thrombocytemia].
    Rager O; Parrens M; Brière J; Lippert E; Milpied N; Pellegrin JL; Viallard JF
    Presse Med; 2011 Dec; 40(12 Pt 1):e507-15. PubMed ID: 21737230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A distinct molecular mutational profile and its clinical impact in essential thrombocythemia and primary myelofibrosis patients.
    Zaidi U; Sufaida G; Rashid M; Kaleem B; Maqsood S; Mukry SN; Khan RZA; Munzir S; Borhany M; Shamsi TS
    BMC Cancer; 2020 Mar; 20(1):205. PubMed ID: 32164591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease.
    Jeryczynski G; Thiele J; Gisslinger B; Wölfler A; Schalling M; Gleiß A; Burgstaller S; Buxhofer-Ausch V; Sliwa T; Schlögl E; Geissler K; Krauth MT; Nader A; Vesely M; Simonitsch-Klupp I; Müllauer L; Beham-Schmid C; Gisslinger H
    Am J Hematol; 2017 Sep; 92(9):885-891. PubMed ID: 28543356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-omics differences in the bone marrow between essential thrombocythemia and prefibrotic primary myelofibrosis.
    Zhang A; Sun T; Yu D; Fu R; Liu X; Xue F; Liu W; Ju M; Dai X; Dong H; Gu W; Chen J; Chi Y; Li H; Wang W; Yang R; Chen Y; Zhang L
    Clin Exp Med; 2024 Jul; 24(1):154. PubMed ID: 38972952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms.
    Yang N; Park S; Cho MS; Lee M; Hong KS; Mun YC; Seong CM; Huh HJ; Huh J
    Ann Lab Med; 2018 Jul; 38(4):296-305. PubMed ID: 29611379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease].
    Melikyan AL; Subortseva IN; Sudarikov AB; Kovrigina AM; Gilyazitdinova EA; Kolosheinova TI; Abdullaev AO; Treglazova SA
    Ter Arkh; 2017; 89(7):4-9. PubMed ID: 28766534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.